Skip to content

CBD: all studies

Page 38 of 38: studies 371 to 375 of 375, newest first. Back to the CBD overview

Research

Delta 9-tetrahydrocannabinol produced discrimination in pigeons.

Pharmacology, Biochemistry, and Behavior 1975 B G Henriksson, J O Johansson, Torbjörn U C Järbe

In an operant situation pigeons learned to peck one response key 90 min after an injection of 0.25mg/kg delta9-tetrahydrocannabinol (delta9-THC) and another key when trained nondrugged. When tested with doses of delta9-THC lwer than the training dose the birds disciminated 0.20 mg/kg of the drug from the nondrugged state but not 0.15 mg/kg or lower doses. The animals were able to discriminate...

Chemical basis of hashish activity.

Science August 7, 1970 Raphael Mechoulam, A Shani, H Edery et al.

A sample of hashish was extracted consecutively with petroleum ether, benzene, and methanol. When tested intravenously in monkeys only the petroleum-ether fraction was active. This material was further fractionated. The only active compound isolated was Delta(1)-tetrahydrocannabinol. Cannabinol, cannabidiol, cannabichromene, cannabigerol, and cannabicyclol when administered together with...

Cannabis Use Patterns in First Episode Psychosis and Schizophrenia: A Scoping Review and Case Series

Jeff W. Jin, Nolan J. Neu, Isaac B. Satz et al. preprint

Background Cannabis use is associated with psychosis development and symptom relapse in persons with schizophrenia spectrum disorders (SCZ). As more U.S. states legalize cannabis and products increase in potency, it is crucial to better understand recent cannabis use patterns in SCZ. Methods We conducted a scoping review of research on cannabis use patterns in SCZ after January 2016 and present...

The FDA Backdoor to MDMA Rescheduling

SSRN Electronic Journal Vincent Joralemon preprint

MDMA is currently a Schedule I controlled substance, the most restrictive category under the Controlled Substances Act. But Lykos Therapeutics' (formerly MAPS PBC) pending New Drug Application for MDMA-assisted therapy as a treatment for PTSD may force the Drug Enforcement Administration's hand: FDA approval supplies the "accepted medical use" that Schedule I drugs are statutorily denied,...

Regulating Psilocybin as Food, Not Drugs

Julia Etkin, Vincent Joralemon preprint

Psilocybin is currently classified as a Schedule I controlled substance under the Controlled Substances Act-the federal designation reserved for substances deemed to have no accepted medical use and a high potential for abuse. Yet by comparative-harm metrics, psilocybin ranks among the safest psychoactive compounds in widespread use, far safer than alcohol and tobacco, both of which are...